Introduction
"It has become standard dogma that surgical intervention is unwarranted once a diagnosis of small cell carcinoma of the lung is made. This view may not be entirely substantiated and there is a growing recognition that limited disease and extensive disease behave differently with respect to therapeutic outcome and this observation may make the reintroduction of surgical approaches to this disease a reality." Anderson and Arentzen, 1980' Surgical management of patients with small cell carcinoma of the lung fell into disrepute after the report of a Medical Research Council trial was published in 19682; the conclusion that surgical resection does not improve long term survival persists to this day. There is evidence, however, that the time has come for a revision of management regimen for patients with small cell carcinoma of the lung,X5 Management was by pulmonary resection and clearance of ipsilateral metastatic lymph nodes in all patients with stage I or II disease. No patient with stage I or II disease received adjuvant chemotherapy or radiotherapy. Patients with stage III disease received adjuvant chemotherapy two weeks after surgery-initially only those with extrathoracic metastases, but 14 in addition had chemotherapy when no intrathoracic metastases were evident after resection. They received cyclophosphamide (1 g/m2), doxorubicin (40 mg/m2), and vincristine (1 mg/m2) at three weekly intervals for three cycles. Responders received further cycles at monthly intervals for up to one year or until they relapsed.
Survival was defined as the time from operation to death or, in the case of survivors, the last clinical review. Actuarial five year survival was estimated by Kaplan-Meier's product limit method.6 Deaths within 30 days ofoperation were included in the estimation of survival data.
Results
The results of pathological staging are shown in table Three of the 97 patients died within 30 days of operation as a consequence of myocardial infarction, pulmonary embolism, and bronchopneumonia consequent on a bronchopleural fistula respectively. A further 25 patients (26%) suffered substantial nonfatal complications (19 bronchopneumonia, five bronchopleural fistula, and one pulmonary embolus).
The cumulative five year survival for the study group as a whole was 16 8% (fig 1) . When the data were analysed according to UICC staging (fig 2) , 35-4% with stage I disease, 22-6% with stage II, but 785 Prasad, Naylor, Walker, Lamb, Cameron, Walbaum We have used resection as a debulking procedure in our patients with stage III disease before adjuvant chemotherapy. The median survival of 17 months exceeds the median survival for both limited stage disease (12 months)'6 and diffuse disease (5-9 months)"''9 reported for chemotherapy alone and indeed for chemotherapy and radiotherapy, 9-16 months.'8202' Debulking may therefore confer some survival value in these patients and merits further investigation.
